688176.SH
亚虹医药-U
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 11.49
−5.82%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 287.1M | 277.1M | 201.6M | 13.8M | 26.1K |
| Cost of Revenue | 78.6M | 72.0M | 49.3M | 2.9M | 7.0K |
| Gross Profit | 208.6M | 205.2M | 152.3M | 10.9M | 19.1K |
| Operating Expenses | |||||
| R&D Expense | 301.8M | 282.6M | 311.9M | 364.6M | 243.9M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 92.0M | 93.4M | 77.3M | 83.1M | 73.7M |
| Selling & Marketing Expense | 283.7M | 272.0M | 185.5M | 34.4M | 14.6M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 684.7M | 654.4M | 559.7M | 444.3M | 307.1M |
| Cost and Expenses | 763.2M | 726.4M | 609.0M | 447.1M | 307.2M |
| Operating Income (EBIT) | (455.0M) | (428.3M) | (383.8M) | (404.0M) | (247.6M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (461.4M) | (433.4M) | (386.8M) | (401.5M) | (245.3M) |
| Income Tax Expense | (500.1K) | (660.5K) | (795.8K) | (668.0K) | 1.3M |
| Bottom Line | |||||
| Net Income | (445.2M) | (416.4M) | (384.1M) | (400.4M) | (246.5M) |
| Earnings from Cont. Ops | (460.9M) | (432.7M) | (386.0M) | (400.8M) | (246.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (445.2M) | (416.4M) | (384.1M) | (400.4M) | (246.5M) |
| Per Share | |||||
| Basic EPS | (CN¥0.79) | (CN¥0.74) | (CN¥0.68) | (CN¥0.70) | (CN¥0.43) |
| Diluted EPS | (CN¥0.79) | (CN¥0.74) | (CN¥0.65) | (CN¥0.67) | (CN¥0.43) |
| Revenue Per Share | CN¥0.51 | CN¥0.49 | CN¥0.36 | CN¥0.02 | CN¥0.00 |
| Shares | |||||
| Basic Shares Outstanding | 562.0M | 562.7M | 564.8M | 572.0M | 573.4M |
| Diluted Shares Outstanding | 562.0M | 562.7M | 564.8M | 572.0M | 573.4M |
| Profitability Metrics | |||||
| EBITDA | — | (405.8M) | (364.0M) | (390.8M) | (239.0M) |
| D&A | — | 22.5M | 19.8M | 13.2M | 8.6M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026